Uterus/Endometrium Cancer
Surgical Treatment
A Molecular Staging Study of Endometrial Carcinoma [GOG 0210]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
Advanced, Persistent or Recurrent Disease
A Phase II Evaluation of Ixebepilone (BMS-247550, [NCI-Supplied Agent, IND #59699, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Cancer [GOG 0129P] Temporarily closed to accrual
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/ G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer [GOG 0209]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of VEGF-Trap (Aflibercept, NSC #724770, IND #BB100137, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Cancer [GOG 0229F] Temporarily closed to accrual
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC #704865, IND #7921) and Temsirolimus (NCI Supplied Agent: NSC #683864, IND #61010)in the Treatment of Recurrent or Persistent Endometrial Carcinoma [GOG 0229G]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus [GOG 238]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Randomixed Phase II Trial Of Temsirolimus or the Combination of Hormonal Therapy plus Temsirolimus in Women with Advanced, Persistent, or Recurrent Endometrial Carcinoma [GOG 0248]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
Sarcomas
A Phase II Evaluation of Trabectedin (Yondelis, R279741, IND #75,111) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas [GOG 087M] Temporarily closed to accrual.
Pricipal Investigator:
S. K. Sharma, MD
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma [GOG 0232C]
Pricipal Investigator:
S. K. Sharma, MD
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN